Aim: Obsessive-compulsive disorder (OCD) is a well-known chronic illness. This study retrospectively investigated 10-year outcomes and associated clinical factors in Japanese OCD patients. We focused on the impact of several sociocultural factors, including medical expenses and insurance systems specific to each country, on the differences or biases in follow-up procedures of OCD.
O BSESSIVE-COMPULSIVE DISORDER (OCD)
is a relatively common and frequently debilitating neuropsychiatric disorder that affects approximately 2% of the general population. 1, 2 OCD is characterized by intrusive and unwanted obsessions and compulsions and by a waxing and waning course of symptoms that rarely remit. 1, 2 Standardized treatments for OCD, including drugs (e.g., [selective] serotonin reuptake inhibitors [S]SRI) and cognitive behavioral therapy (CBT), have been well established and adopted worldwide. 3 Although the effectiveness of these treatments has been verified in short-term randomized controlled trials, 3 longerterm treatment outcomes in OCD remain unclear. Follow-up studies conducted over 2 years in Western countries have revealed wide variation in the rates of patients who experience full remission, ranging from 12% to 86%. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] This variation may be a result of the substantial methodological differences in treatment procedures and assessment methods in these studies, as well as inconsistencies in the definition of full remission. Previous studies have also identified clinical, demographic, phenomenological, and psychopathological features as significant long-term response predictors. [7] [8] [9] [10] [14] [15] [16] However, there appears to be considerable inconsistency in these predictors between studies.
Several sociocultural factors, including medical expenses and insurance systems specific to each country, may also cause differences or biases in follow-up procedures. All residents of Japan are covered by a national health-care system, and semi-governmental insurance organizations typically meet up to 70% of the cost of services received by an individual. 17 In addition to Japan's universal health insurance coverage, there is no strict regulation of referrals to medical services. Thus, even patients with OCD in remission often continue to receive follow-up assessments. This system allows patients with OCD to receive consistent long-term treatment and therapeutic strategies, greatly facilitating follow-up studies.
In the present study, we sought to retrospectively investigate long-term outcomes in 79 Japanese patients with OCD admitted to our hospitals who had received standardized OCD treatment from the same OCD specialists continuously for at least 10 years. The study had three aims: (i) clarifying 10-year treatment outcomes, including remission rates, in Japanese patients; (ii) identifying the clinical factors that predict remission of OCD or nonresponsiveness to treatment; and (iii) investigating the impact of sociocultural factors.
METHODS

Ethical considerations
All of the procedures in the current study complied with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. This study was approved by the ethics committee at Osaka City University along with that of Hyogo College of Medicine. Detailed explanations of the study procedures were provided to each participant at the time we received their informed consent.
Patients
The patients in this retrospective study were 79 Japanese OCD patients (26 men and 53 women) who were admitted to Osaka City University Hospital between May 1998 and March 2004 and received specialized treatment for OCD for more than 10 continuous years. All of the patients either self-referred or were referred by general psychiatrists to our hospital. The inclusion criteria for this study were: (i) obsessive-compulsive symptoms being the chief complaint at their initial hospital visit; (ii) meeting DSM-IV diagnostic criteria for OCD, 1 confirmed by the Structured Clinical Interview for DSM-IV Axis I Disorders Patient Edition (SCID-P) 18 ; (iii) having no treatment history or at least 3 months of treatment discontinuation prior to the initial visit to our hospital; and (iv) providing written informed consent to participate in the study. After the 10-year period, patients had to meet two additional criteria for inclusion in the final analysis: (i) receiving continuous treatment at the Hyogo College of Medicine Hospital after April 2010 (owing to the relocation of their OCD specialists from Osaka City University Hospital); and (ii) having less than 6 months of treatment withdrawal during the 10 years of treatment (owing to the possible discontinuation of treatments, particularly pharmacotherapy, and/or difficulty with continuous follow-up assessments). The exclusion criteria were: (i) naturalistic dropout from treatments or more than 6-month treatment withdrawal during the period; (ii) the presence of a significant neurological illness other than tic disorder; (iii) history of past or current drug abuse or dependence; (iv) a serious concomitant general medical condition that could contraindicate antiobsessional drug treatment; and (v) a current or previous diagnosis of schizophrenia or another psychotic disorder.
Consequently, 79 patients were enrolled in the final study. Of the 122 excluded patients, 14.8% were excluded because they did not meet the inclusion criteria or met the exclusion criteria of the study. The others dropped out prematurely during the 10-year period, usually because of difficulties in regularly attending our hospital owing to geographic distance, self-initiated transfer to other hospitals, or discontinuation of referral to the hospital for unknown reasons. autism spectrum disorders (ASD) was determined according to the DSM-IV-TR criteria for autistic disorder, Asperger's disorder, or pervasive developmental disorder not otherwise specified. This diagnostic assessment was conducted in face-to-face interviews with each patient and their caregivers taking into account multiple information sources, such as clinicians' observations, developmental history, selfreports, and other reference materials (e.g., report cards from elementary or junior high school). In the case of patients with suspected ASD, well-trained psychiatrists (H. M., K. M., K. H.), including the psychiatrist in charge of each case, discussed each case and determined whether they should be diagnosed as comorbid OCD and ASD based on DSM-IV-TR criteria.
In subsequent interviews, we investigated patients' involvement behaviors (IB), including asking caregivers for reassurance, forcing caregivers to participate in their rituals, and forcing caregivers to assist in avoidance behaviors according to the patient's rules or demands. The presence of IB was determined by the assessment procedure described in our previous study, 19 taking into account a definition of family accommodation as proposed in earlier studies. 20, 21 The initial severity of obsessive-compulsive symptoms was measured using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). 22, 23 A rating for each OCD symptom was obtained using the Japanese version of the Y-BOCS symptom checklist. 24 Each of the categories was scored as 0 (absent), 1 (present), or 2 (predominant), according to previous studies investigating symptom dimensions. 25, 26 Each participant's degree of insight into their own symptoms was also evaluated using the Insight questionnaire of the Y-BOCS. 22, 23 For each participant, lifetime comorbidity of major depressive disorder (MDD) and any other personality disorder (PD) was assessed using the SCID-P 18 and the Structured Clinical Interview for DSM-IV Axis II Personality Disorders, 27 respectively. Depressive and anxiety symptoms were assessed using the Zung Self-Rating Depression Scale 28 and the State-Trait Anxiety Inventory. 29 Treatment procedures and longitudinal evaluation of treatment outcomes Figure 1 shows a brief summary of the treatment procedure in this study. After pretreatment assessments and psychoeducation, each participant was treated with a standardized combination of SRI (e.g., clomipramine [CMI] , fluvoxamine [FLV], or paroxetine [PXT]) and CBT. This procedure was performed according to standardized treatment protocols, modified for Japanese OCD patients using APA treatment guidelines. 3 Treatment was typically initiated with daily doses of 25 mg CMI or FLV, or 10 mg PXT. If the medication was tolerated, the dosage was gradually increased over 4 weeks to a maximum of 250 mg/day for CMI or FLV, or 50 mg/day for PXT. CBT consisting of exposure and response prevention was subsequently initiated with informational interventions designed to orient patients to a basic cognitive-behavioral model of OCD, along with behavioral analysis. CBT sessions were scheduled weekly or biweekly, and consisted of 13-20 sessions conducted by psychologists. Booster sessions were also added for patients who were not responsive to the standard CBT sessions, or who showed signs of early relapse.
Patients who were non-responsive to CBT and two trials of SSRI at maximum doses (as assessed by the reduction rate of Y-BOCS [< 10%] and a Clinical Global Impressions [CGI] -Improvement score of *Number of subjects who completed the 10-year treatment. CBT, cognitive behavioral therapy; SSRI, selective serotonin reuptake inhibitors.
3 or 4) were treated with augmenting atypical antipsychotics, including aripiprazole, olanzapine, quetiapine, and risperidone. 30 Maintenance treatment for responders after the first year of treatment (Y-BOCS > 35%) included supportive psychotherapy and CBT booster sessions every 1-3 months, with gradual discontinuation of medication. Additional CBT sessions were added every 2-4 weeks and drug treatment optimization continued for patients who showed poorer responses in the first year of treatment (Y-BOCS < 35%) until patients met the criteria for responders. This treatment regimen continued for each patient during the 10-year period.
Follow-up assessments were continued to evaluate all patients systematically at least once every 5-7 months, although the frequency and timing varied because of patients' difficulty keeping appointments. During follow up, patients were assessed using the Y-BOCS and CGI -Improvement scale. All evaluations were performed by psychiatrists in faceto-face interviews with patients, with a relative present.
At 10 years after the initiation of treatment, we evaluated patients and classified them into three categories: full remission, partial remission, or nonresponse of symptoms. Consistent with the definition proposed by Catapano et al., 6 full remission was defined as a Y-BOCS Total score of <8 for at least 8 consecutive weeks, a CGI score of 1 or 2, and a failure to fulfill the DSM-IV criteria for OCD. Partial remission was defined as a Y-BOCS Total score ranging from 8 to 15 for at least 8 weeks and a CGI score of 2 or 3. Non-responders were defined as still meeting the OCD diagnostic criteria, having a Y-BOCS Total score >16, and a CGI score of 4 at the time of the end-point assessments.
Similarly, relapse was defined as a re-emergence of OCD symptoms after at least partial remission, with a Y-BOCS score of >15 for at least 4 consecutive weeks, 6,9 a CGI score of 5, 6, or 7, and fulfilling the DSM-IV OCD criteria. If a patient exhibited remission but relapsed afterwards, they were categorized according to the definition of 'full remission,' 'partial remission,' or 'non-response' at 10 years from the initiation of treatment.
Statistical analyses
Significant group differences for parametric variables were evaluated using one-way analysis of variance (ANOVA), employing the multiple comparisons procedure. For categorical data, we conducted the χ 2 -test with Yates's correction for discontinuity or Fisher's exact test (for minimum expected cell sizes ≤ 5). The cumulative probability of remission from OCD was determined using lifetime tables for survival analysis. Predictors of remission were also determined using Cox proportional hazards regression (forward stepwise). In addition, we tested nominal variables using Cox proportional regression. All analyses were conducted using SPSS 20.0 (IBM, Chicago, IL, USA). The criterion for statistical significance was set at P < 0.05.
RESULTS
Clinical characteristics of dropped-out patients
Patients who were included in the analysis were significantly more likely to be female than patients who were excluded (P < 0.05). Except for sex ratio, there were no significant differences in the demographic profiles, clinical features, or phenomenological characteristics (including distribution and severity of OCD symptoms) between the 79 patients included in the study and the 122 patients who were excluded from the study.
Course of 10-year treatment outcome (Fig. 2) Mean Y-BOCS Total scores gradually decreased across the course of treatment, with the most apparent improvements observed during the first year. The survival curve for the proportion of fully remitted OCD patients during the 10-year study period (Fig. 2) indicates that the rate of patients achieving full remission increased each year. The cumulative probability of full remission was 0.05 at the beginning of year 2 (at the end of year 1), 0.22 at the beginning of year 3 (at the end of year 2), 0.34 at the beginning of year 4 (at the end of year 3), 0.48 at the beginning of year 6 (at the end of year 5), 0.54 at the beginning of year 8 (at the end of year 7), and 0.56 at the beginning of year 10 (at the end of year 9). Therefore, of the patients, 44 (56%) patients experienced 'full remission' maintained for at least 1 year during the 10-year period.
Comparisons of clinical and treatment features among the groups categorized by 10-year outcome (Tables 1, 2) Patients were divided into three groups according to their 10-year outcome. Thirty-eight patients (48%) were classified as being in full remission, 29 (37%) were classified as partially remitted, and the remaining 12 patients (15%) were classified as nonresponders. Tables 1 and 2 show the comparisons of demographic profiles, clinical features, and treatment-related variables in each group.
Compared with the full remission group, patients in the non-response group had a significantly earlier age of onset (F[2, 78] = 3.3, P < 0.05) and lower GAF scores (F[2, 78] = 13, P < 0.01). Moreover, compared with the full remission group, a greater proportion of patients in the non-response group had poorer insight (χ 2 = 14.8, P < 0.01), a lifetime history of tic disorder (χ 2 = 7.62, P < 0.05) or ASD (χ 2 = 7.19, P < 0.05), or any PD (χ 2 = 14.8, P < 0.01) or IB (χ 2 = 12.4, P < 0.01; Table 2 ). Even though no significant differences were observed between the three groups in Total Y-BOCS score at pretreatment assessment, Trait (F[2, 78] = 5.7, P < 0.01) and State (F[2, 78] = 5.6, P < 0.01) scores on the State-Trait Anxiety Inventory were significantly higher in non-responders compared with fully remitted patients. Regarding OCD symptoms, fully remitted patients showed a higher prevalence of sexual obsessions (F[2, 78] = 3.7, P < 0.05) and checking compulsions (F[2, 78] = 4.4, P < 0.05) compared with non-responders. Conversely, hoarding obsessions (F[2, 78] = 3.3, P < 0.05) and compulsions (F[2, 78] = 3.1, P < 0.05) were most frequently detected in the non-response group.
During the 10-year follow up, all patients received pharmacotherapy according to the standardized treatment procedure. There were no significant differences in the distributions of predominant SRI in the three groups (FLV/PXT/CMI: full-remission, n = 18/16/4; partial remission, n = 15/11/3; nonresponse, n = 6/4/2). However, the mean maximum dosages of both FLV (154.2 AE 40.4 mg/day) and PXT (35.0 AE 5.2 mg/day) in the full remission group were significantly lower than those in the partial remission group (FLV, 193.3 AE 32.0 mg/day; PXT, 40.9 AE 5.4 mg/day) and the non-response group (FLV, 208.3 AE 58.5 mg/day; PXT, 42.5 AE 5.0 mg/day). On the other hand, even though there were significant group differences in the rates of patients who required augmentation of antipsychotics (Table 2) , the mean maximum doses (chlorpromazine equivalent) of augmenting antipsychotics were not significantly different between the groups (Table 1) .
Nineteen (24%) of the 79 patients dropped out of CBT prematurely ( Table 2 ). The non-response group showed the highest rates of premature dropout from CBT (χ 2 = 6.54, P < 0.05) among the groups. This group also exhibited the greatest increase in the proportion of patients requiring SSRI treatment augmented with antipsychotic agents (χ 2 = 14.6, P < 0.01) and inpatient admission (χ 2 = 18.5, P < 0.01). In addition, partially remitted patients and non-responders were more likely than those in the full remission group to relapse during the follow-up period (χ 2 = 17.2, P < 0.01).
Predictive factors of 10-year outcome (Figs 3, 4)
Cox proportional hazards regression using the forward stepwise (likelihood ratio) method suggested that GAF scores at initial assessments (hazard ratio Years since the initiation of treatments The results revealed differences in the survival curves for the cumulative proportion of remitted patients among those with better responses (improvement rate of Total Y-BOCS > 35%) compared with those exhibiting poorer responses after 1 year of treatment (Fig. 3 ). There were also different survival curves for those with IB compared with those without IB (Fig. 4) . However, no additional significant predictors were identified.
DISCUSSION
To our knowledge, this is the first study to investigate the long-term outcomes of people with OCD in a non-Western country other than India. 7, 12 As a result of Japan's public insurance system, the current study had the advantage of recruiting patients who had received continuous standardized treatment across a 10-year period at a specialized OCD clinic.
In long-term treatment studies with follow-up periods of more than 2 years conducted in Western countries, the reported probability of full remission ranged from 12% to 86%. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] The rate of full remission in OCD patients in this study (48.1%) was around the middle of this published range. Given previously reported relapse rates ranging from 25% to 59%, [6] [7] [8] [9] [10] [11] the rate found in the current study (27.8%) supports the possibility that continuous follow-up treatment (facilitated by the Japanese insurance system) may be particularly effective for Tests with Yates's correction for discontinuity or Fisher's exact test, if the minimum cell size was < 5. CBT, cognitive behavioral therapy; F, full remission; N, non-response; NS, not significant; OCD, obsessive-compulsive disorder; P, partial remission. © 2018 The Author Psychiatry and Clinical Neurosciences © 2018 Japanese Society of Psychiatry and Neurology preventing relapse of OCD symptoms. However, since the results of this study are not national data, it is hard to say that it reflects the universal situation of Japan. In addition, this issue warrants further investigation to examine the role of other potentially important sociocultural differences, such as traditional family style, social systems for increasing awareness of OCD, and treatment-seeking behavior patterns, between countries. Moreover, given the considerable methodological differences between studies in terms of sample characteristics, study design, variety of treatment procedures and assessment methods, and definitions of remission, this result should be interpreted cautiously. Indeed, an international consensus for defining treatment responses in OCD was recently proposed to ameliorate these methodological issues. 31 In particular, the differing clinical characteristics of patients and differing definitions of remission between studies may account for the wide variations in outcomes. 7 Outcomes in OCD may be affected by illness duration at baseline, 6, 10, 13, 16 as several studies reporting lower remission rates (<20%) have included patients with OCD who were chronically ill for >15 years. 5, 8, 9 It has also been widely reported that the length of follow up can have a considerable impact on long-term outcomes in OCD. Studies with follow-up periods of <5 years have reported remission rates of 12% to 38%, 6, 8 whereas studies with longer follow-up periods (>10 years) reported full remission rates ranging from 42% to 86%. 11, 12, 32 To our knowledge, the only exception is a study by Skoog and Skoog, 14 which examined the naturalistic course of OCD for more than 40 years. Their results are consistent with the findings of the Kaplan-Meier survival analysis in the current study, revealing that the proportion of fully remitted patients increased each year (Fig. 2) . In accord with these results, Marcks et al. 11 reported a gradual increase in remission rates over time, depending on the length of follow up. However, substantial differences in full remission rates were observed between the findings of a 5-year follow-up study by Eisen et al. 9 and the results of Cherian et al. 7 Cherian et al. 7 suggested that the majority of patients who remitted did so within 2 years. This is consistent with the current findings, suggesting that the improvement rate after 1 year was a significant predictor of remission within 10 years. These findings highlight the importance of early detection and intervention with effective treatment to improve long-term outcomes in OCD. 7, 11, 33 However, other studies have suggested that short-term treatment responses have no predictive value in the long-term course of OCD. 4, 13 All of the patients in the current study received a recommended, internationally standardized treatment regimen. 3 However, the differential effects of initial therapeutic interventions (SSRI alone, CBT alone, or a combination of the two) remain controversial. 10 Nevertheless, it is likely that subsequent treatment strategies across the follow-up period have a substantial effect on long-term outcomes in OCD. For instance, O'Sullivan et al. 33 followed up patients 6 years after receiving exposure therapy, along with clomipramine or placebo. Their results suggested that neither clomipramine nor placebo had significant effects on treatment outcome, but greater exposure and response prevention, and better homework compliance were associated with better treatment outcomes. 33 Thus, it is possible that maintenance CBT during follow up may elevate OCD remission rates. Moreover, follow-up treatment strategies should be standardized to improve the reliability of future studies investigating long-term outcomes in OCD.
Our findings also support the existence of common predictive factors for poorer long-term outcomes. As reported in samples in Western countries, these factors included earlier age of onset, 8, 10, 14 lower Global Assessment of Functioning Scale or quality of life scores, 14, 16 presence of hoarding symptoms 9, 25 and IB, 16, 34 poorer insight, 8, 35 and comorbidity with ASD 15 and PD 6,9 at baseline. The current results suggest that the presence of IB, along with lower GAF scores at initial assessments, are particularly strong significant predictors of poor response. This replicates our previous finding that the presence of IB or hoarding symptoms was associated with poorer short-term (<1 year) outcomes in OCD. 19, 26 Another study found that elevated ASD traits also tended to negatively influence 1-year outcomes in OCD. 36 These findings raise the possibility that psychopathological features, social and interpersonal functioning, and psychosocial background may have important impacts on outcomes in OCD. In addition, the current results indicate that this phenomenon operates across different sociocultural contexts, including countries with different national medical insurance systems. Thus, it appears that better social and interpersonal abilities, and better social adaptation at the baseline, are associated with favorable outcomes in people with OCD, regardless of sociocultural context. Finally, our study revealed that patients classified as exhibiting partial remission were significantly more likely than those classified as exhibiting full remission to have a history of relapse during the 10-year period. This is consistent with the findings of a 5-year follow-up study by Eisen et al., 9 which reported that the likelihood of relapse was 25% higher for patients in partial remission compared with those in full remission. Thus, people with OCD may be vulnerable to relapse following standardized treatment for OCD if they continue to experience subclinical OCD symptoms. 7, 9 Therefore, these findings also emphasize the importance of adequate therapeutic intervention targeting full remission for better long-term outcomes in OCD. Further clinical trials are needed to develop optimized therapeutic interventions to facilitate relapse prevention in OCD.
The current study contained several limitations that should be considered when interpreting the results. First, because this was a naturalistic followup study, a considerable proportion of patients with OCD dropped out of the study. Regardless of the absence of significant differences in demographic profiles, clinical features and phenomenological characteristics other than sex between patients who dropped out and those who were included, this may have led to sampling bias. Thus, patients with OCD with higher motivation or better treatment adherence may have been more likely to continue to participate in the study. Thus, further studies with larger samples are required to confirm whether our results can be generalized to a more diverse population in Japan, including individuals with OCD who do not seek treatment. Second, the relatively small sample size in this study may have limited its statistical power. This further supports the necessity of verifying the current results in further studies with larger sample sizes. The inclusion of a control group may also be beneficial for examining the therapeutic effects of the naturalistic time course or other nonspecific treatment factors on the long-term outcomes of OCD.
Third, the measures of timing of remission and relapse in the current study may not have been precise, because the patients were assessed once within a maximum of 7 months. Thus, future studies should conduct more frequent assessments.
Fourth, no assessment of 'recovery' was included in the current study. However, recent research on OCD suggests that achieving 'recovery' means not meeting diagnostic criteria for at least 1 year. 31 While we applied a definition of 'full remission' used in a previous study, 6 the time period included in the definition of remission ('at least 8 consecutive weeks') may not be an accurate reflection of the actual clinical remission of OCD. Thus, the methodological problems and limitations inherent in the definitions adopted in recent studies of OCD outcomes should be taken into account.
Fifth, regardless of the limited availability of assessment tools in Japanese at the time we began the current research, reliable ASD diagnosis should be made using structured interview methods.
Finally, compared with the findings of previous studies in Western populations, we detected several different trends in the predictors associated with treatment outcomes. For example, we found that patients experiencing full remission were significantly more likely to have sexual obsessions than the non-response group. In contrast, studies in some other countries reported that sexual/religious obsessions predicted poorer long-term outcomes. 4 Further studies using a multi-dimensional approach to assess the relation between OCD symptomatology and OCD course could clarify the potential effects of cross-cultural differences on these factors between Japan and Western countries. 7 It should be noted that a previous study in our lab confirmed the crosscultural stability of symptom structures in Japanese patients with OCD.
In conclusion, the present study had the advantage of continuous and regular follow up by OCD specialists facilitated by the public health insurance system of Japan. In our study sample, remission and relapse rates, as well as the factors predicting poorer outcomes, including earlier age of onset, lower Global Assessment of Functioning Scale, poorer insight, presence of hoarding symptoms and IB, and comorbid ASD and PD at initial assessments, were consistent with those reported in Western countries. Consistent with previous studies, the current study highlights the importance of early detection and intervention with effective and optimized treatment to improve long-term outcomes in OCD. 7, 11, 33 Thus, the present findings support the transcultural stability of long-term outcomes in OCD.
Further research is required to develop methods for facilitating the help-seeking behaviors of individuals with nonclinical OCD. Furthermore, the current results support the notion that standardized followup treatment strategies and psychosocial interventions are necessary for full remission from OCD and the prevention of relapse.
